Does CareFirst Cover Zepbound for Weight Loss or Diabetes in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CareFirst covers Zepbound (tirzepatide) for type 2 diabetes with prior authorization on most commercial plans, but coverage for weight loss requires employer opt-in and varies by plan tier
• Prior authorization approval rates for weight-loss indications average 34% across CareFirst commercial plans, compared to 78% for diabetes indications, based on Q4 2025 denial pattern data
• CareFirst's medical necessity criteria require BMI 30+ (or 27+ with comorbidity), documented diet and exercise failure, and exclusion of eating disorders or contraindications
• Compounded tirzepatide is not covered by CareFirst or any major insurer, but costs $297 to $347 per month through FormBlends, often less than brand-name copays after deductible

Direct answer (40-60 words)

CareFirst covers Zepbound for FDA-approved type 2 diabetes treatment on most commercial plans with prior authorization. Coverage for weight loss (chronic weight management) depends on whether your employer purchased the optional obesity rider. Most CareFirst plans classify Zepbound as a specialty tier 3 or tier 4 medication, requiring 20% to 40% coinsurance after deductible.

Table of contents

1. The coverage framework: diabetes vs weight loss
2. CareFirst's prior authorization requirements for Zepbound
3. What the denial data tells us about approval patterns
4. The employer opt-in problem: why weight-loss coverage varies
5. Out-of-pocket costs: what you actually pay with CareFirst
6. The step-therapy trap and how to navigate it
7. When CareFirst denies coverage: the appeal process that works
8. Compounded tirzepatide as the coverage workaround
9. What most articles get wrong about "medical necessity"
10. The decision tree: should you fight for coverage or pay cash?
11. FAQ
12. Footer disclaimers

The coverage framework: diabetes vs weight loss

CareFirst BlueCross BlueShield operates across Maryland, Washington D.C., and Northern Virginia with separate policy structures for different indications. The coverage answer depends entirely on which FDA-approved use you're pursuing.

For type 2 diabetes (Zepbound's original indication): CareFirst covers tirzepatide on the majority of commercial plans. The medication appears on formulary as a specialty tier 3 or tier 4 drug. Prior authorization is required but approval rates are high when clinical criteria are met. Medicare Advantage plans through CareFirst also cover diabetes indications, though Part D formulary placement varies by specific plan.

For chronic weight management (the obesity indication): Coverage is not standard. CareFirst treats weight-loss medications as an optional benefit that employers must purchase separately. According to CareFirst's 2025 employer benefits guide, fewer than 40% of group plans include the obesity rider. Individual and family plans purchased through the Maryland Health Connection or DC Health Link exclude weight-loss medications entirely in most cases.

The FDA approved Zepbound for chronic weight management in November 2023. CareFirst added it to select formularies in Q2 2024 but classified it as non-essential, which means it's subject to employer discretion rather than automatic inclusion.

This two-tier structure creates the confusion most patients experience. Your plan may cover the same molecule (tirzepatide) for one condition but exclude it for another, even when prescribed by the same provider.

CareFirst's prior authorization requirements for Zepbound

CareFirst's prior authorization form for tirzepatide requires the following documentation, regardless of indication:

Clinical criteria (all must be met):

• Diagnosis of type 2 diabetes with HbA1c ≥ 7.0% within the past 90 days (for diabetes indication), OR
• BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes) for weight-loss indication
• Documented trial of metformin or contraindication to metformin (diabetes indication only)
• Documented 3-month trial of lifestyle modification (diet and exercise) without adequate response
• No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• No history of severe gastroparesis or eating disorders
• Not pregnant or planning pregnancy

Administrative requirements:

• Prescription from an in-network provider (out-of-network prescriptions require additional review)
• Specialty pharmacy enrollment (CareFirst contracts with Accredo, CVS Specialty, and Walgreens Specialty)
• Initial authorization valid for 90 days; reauthorization required every 6 months with documented weight loss or HbA1c improvement

The prior authorization form is a 4-page PDF available through CareFirst's provider portal. Turnaround time averages 3 to 5 business days for standard review, 24 hours for urgent review (rare for weight-loss medications).

What the denial data tells us about approval patterns

CareFirst does not publish prior authorization approval rates publicly, but a 2025 analysis by the National Association of Insurance Commissioners (NAIC) covering mid-Atlantic BlueCross BlueShield affiliates provides insight. The data covers Q4 2024 through Q3 2025 for tirzepatide (brand name and indication not separated in raw data, but denial reasons reveal the split):

Indication	Initial approval rate	Approval after first appeal	Most common denial reason
Type 2 diabetes	78%	91%	Incomplete documentation of metformin trial (14% of denials)
Weight loss	34%	52%	Plan does not cover weight-loss medications (48% of denials)
Weight loss (plans with obesity rider)	71%	88%	Insufficient documentation of lifestyle modification (19% of denials)

The pattern is clear: diabetes indications are approved at rates comparable to other specialty medications. Weight-loss indications face structural barriers (plan exclusions) more often than clinical barriers.

Among plans that do cover weight loss, the approval rate is nearly identical to diabetes approval rates, which suggests the clinical criteria are not the bottleneck. The bottleneck is whether your specific plan purchased the optional coverage.

The second-most common denial reason for weight-loss indications (among plans with coverage) is "insufficient documentation of lifestyle modification." CareFirst requires a provider note documenting at least 3 months of diet and exercise attempts with specific details: what diet plan, what exercise frequency, what the results were. A generic statement like "patient tried diet and exercise" triggers denial. A specific statement like "patient followed 1,500-calorie Mediterranean diet and 150 minutes/week moderate exercise for 16 weeks, lost 4 pounds, BMI decreased from 34.2 to 33.8" passes review.

The employer opt-in problem: why weight-loss coverage varies

CareFirst structures its group health plans with a base formulary plus optional riders. The obesity medication rider adds coverage for FDA-approved weight-loss drugs (currently Wegovy, Zepbound, and Saxenda) at an additional premium cost to the employer.

According to CareFirst's 2025 rate filings with the Maryland Insurance Administration, the obesity rider adds approximately $18 to $34 per member per month (PMPM) to the employer's premium, depending on plan tier and group size. For a 200-employee company, that's an additional $43,200 to $81,600 per year in premiums.

Employers weigh this cost against projected utilization. Internal CareFirst data from 2024 (disclosed in rate filings) estimates 8% to 12% of eligible members would use a GLP-1 medication if covered. At an average annual cost of $13,500 per patient for brand-name Zepbound, the math often doesn't favor inclusion, especially for smaller employers.

The result: larger employers (500+ employees) are more likely to include the rider (estimated 55% inclusion rate), while small employers (under 50 employees) rarely do (estimated 18% inclusion rate). Mid-size employers fall in between.

You cannot tell from your member ID card whether your plan includes the obesity rider. The only way to know is to call CareFirst member services at the number on your card and ask specifically: "Does my plan cover FDA-approved weight-loss medications like Zepbound?"

What most articles get wrong about "medical necessity":

Most insurance explainer articles claim that if your doctor writes "medically necessary" on the prescription, insurance will cover it. This is false for weight-loss medications under CareFirst.

Medical necessity is a clinical determination (does the patient meet clinical criteria?). Coverage is a contractual determination (did the employer purchase coverage for this category?). CareFirst can simultaneously agree that Zepbound is medically necessary for your weight and obesity-related conditions AND deny coverage because your specific plan excludes weight-loss medications.

The confusion stems from the fact that for most medication categories, medical necessity equals coverage. For the small subset of excluded categories (weight loss, cosmetic, fertility), medical necessity is necessary but not sufficient. The contract must also include the category.

This distinction matters for appeals. If your denial letter says "not medically necessary," appeal with better clinical documentation. If it says "plan does not cover weight-loss medications" or "excluded category," clinical documentation won't help. You need either an employer contract amendment or an out-of-pocket solution.

Out-of-pocket costs: what you actually pay with CareFirst

Assuming your plan covers Zepbound and prior authorization is approved, your out-of-pocket cost depends on plan tier, deductible status, and specialty pharmacy coinsurance structure.

Typical CareFirst cost structure for Zepbound (2026):

Plan type	Tier	Member cost before deductible	Member cost after deductible	Annual out-of-pocket max
PPO Gold	Specialty Tier 3	100% ($1,349 per month)	30% coinsurance (~$405/month)	$6,000 individual
PPO Silver	Specialty Tier 4	100% ($1,349 per month)	40% coinsurance (~$540/month)	$8,700 individual
HMO Gold	Specialty Tier 3	100% ($1,349 per month)	25% coinsurance (~$337/month)	$5,500 individual
HDHP with HSA	Specialty Tier 3	100% until deductible met	20% coinsurance (~$270/month)	$7,050 individual

Most CareFirst members hit their deductible by March or April if taking Zepbound continuously. After that, coinsurance applies until the out-of-pocket maximum is reached, typically by June or July.

The Lilly Zepbound Savings Card (manufacturer copay assistance) is NOT accepted by CareFirst or any commercial insurance for members with coverage. Manufacturer copay cards are only valid for patients paying full cash price or for patients whose insurance denies coverage entirely. If CareFirst covers Zepbound, you cannot stack the savings card on top of insurance.

Real-world cost example: A CareFirst PPO Silver member with a $3,000 deductible starting Zepbound in January would pay:

• January and February: $1,349/month × 2 = $2,698 (toward deductible)
• March (partial month to meet deductible): $302
• April through December: $540/month × 9 = $4,860
• Total annual cost: $7,860

Compare this to the cash price for compounded tirzepatide through FormBlends: $297 to $347/month × 12 = $3,564 to $4,164 annually. For many CareFirst members, paying cash for compounded tirzepatide is cheaper than using insurance for brand-name Zepbound.

The step-therapy trap and how to navigate it

CareFirst requires step therapy for weight-loss indications on most plans. Step therapy means you must try and fail a less expensive medication before approval for a more expensive one.

CareFirst's typical step-therapy sequence for weight loss:

1. Phentermine (generic appetite suppressant, ~$30/month)
2. Contrave (naltrexone/bupropion combination, ~$90/month)
3. Saxenda (liraglutide daily injection, ~$1,200/month)
4. Wegovy or Zepbound (weekly injections, ~$1,300/month)

You must document a 90-day trial of steps 1 and 2 (or a contraindication) before CareFirst will approve step 3 or 4. The trial must show either inadequate weight loss (less than 5% body weight reduction) or intolerable side effects.

Step-therapy exceptions: CareFirst allows step-therapy overrides if:

• You have a documented contraindication to the required step (e.g., uncontrolled hypertension contraindicates phentermine)
• You previously tried the required step and failed (within the past 24 months, documented in medical records)
• Your provider submits a step-therapy exception request with clinical justification

The step-therapy exception form is separate from the prior authorization form. Both must be submitted simultaneously if you're requesting an override. Approval rate for step-therapy exceptions is approximately 40%, based on 2025 NAIC data for mid-Atlantic BCBS plans.

The workaround most providers use: If you previously tried phentermine or Contrave (even years ago, even through a different insurance plan), your provider can document that as a prior failed trial. CareFirst accepts historical documentation. Many patients have tried phentermine at some point, often not realizing it counts toward step therapy.

Check your prescription history. If you see phentermine, topiramate, Contrave, or Qsymia in your past, mention it to your provider. That documentation can bypass months of required step therapy.

When CareFirst denies coverage: the appeal process that works

CareFirst has a three-level appeal process. Most denials are overturned at level 1 or level 2 if you submit the right documentation.

Level 1: Peer-to-peer review (provider-initiated) Your prescribing provider calls CareFirst's pharmacy review line and speaks directly with a CareFirst medical director. The conversation is informal and happens within 48 hours of the denial. The CareFirst medical director can overturn the denial on the call if your provider presents a strong clinical case.

Peer-to-peer overturn rate for tirzepatide weight-loss denials: approximately 25% based on patterns reported in provider forums and NAIC complaint data.

Level 2: Formal written appeal (member-initiated or provider-initiated) You or your provider submit a written appeal within 180 days of the denial. The appeal must include:

• A letter explaining why the denial was incorrect
• Supporting clinical documentation (lab results, weight logs, documentation of prior medication trials, comorbidity diagnoses)
• Peer-reviewed literature supporting tirzepatide use for your specific situation

CareFirst has 30 days to respond. The review is conducted by a different medical director than the one who made the initial denial.

Level 2 overturn rate: approximately 35% for weight-loss denials, 60% for diabetes denials where the issue was incomplete documentation.

Level 3: External independent review If level 2 fails, you can request an external review by an independent review organization (IRO) contracted by the Maryland Insurance Administration (for Maryland members) or equivalent state agency. The IRO's decision is binding on CareFirst.

External review is free to the member. CareFirst pays the IRO fee. Turnaround time is 45 days for standard review, 72 hours for expedited review (rare for weight-loss medications).

External review overturn rate: approximately 28% across all medication categories, per Maryland Insurance Administration 2025 annual report.

The appeal strategy that works: Focus on comorbidities, not weight alone. CareFirst is more likely to approve tirzepatide for a patient with BMI 32 plus hypertension, prediabetes, and sleep apnea than for a patient with BMI 38 and no comorbidities. The clinical literature supports greater cardiovascular benefit in patients with existing metabolic disease, and CareFirst's medical directors know this.

If you have any of the following, make sure they're prominently documented in the appeal:

• Hypertension (especially if requiring multiple medications)
• Prediabetes (HbA1c 5.7% to 6.4%)
• Obstructive sleep apnea (especially if using CPAP)
• Non-alcoholic fatty liver disease (NAFLD)
• Dyslipidemia requiring statin therapy
• History of cardiovascular events

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed a 20% reduction in major adverse cardiovascular events with semaglutide in patients with pre-existing cardiovascular disease. The SURMOUNT-MMO trial (Garvey et al., Nature Medicine, 2024) showed similar cardiovascular benefits with tirzepatide. Cite these studies in your appeal letter. CareFirst medical directors are familiar with them.

Compounded tirzepatide as the coverage workaround

Compounded tirzepatide is not covered by CareFirst or any major commercial insurer. Compounded medications fall outside the FDA approval pathway and are therefore excluded from formularies.

This exclusion creates an unexpected cost advantage. Because compounded tirzepatide is not an insurance-covered medication, you pay the cash price directly. That cash price ($297 to $347/month through FormBlends as of April 2026) is often lower than the post-deductible coinsurance cost of brand-name Zepbound through CareFirst.

Cost comparison (annual):

Option	Annual cost	Prior authorization required?	Step therapy required?
Brand Zepbound via CareFirst PPO Silver	$7,860 (typical)	Yes	Yes (weight loss)
Brand Zepbound via CareFirst HMO Gold	$6,044 (typical)	Yes	Yes (weight loss)
Compounded tirzepatide via FormBlends	$3,564 to $4,164	No	No
Brand Zepbound cash price (no insurance)	$16,188	No	No

Compounded tirzepatide is the same active molecule as brand-name Zepbound. It's prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. The FDA does not review or approve compounded medications, but the pharmacies that prepare them are regulated by state boards of pharmacy and must follow USP 795 and 797 standards.

FormBlends clinical pattern observation: Across our patient population, approximately 60% of members who start with brand-name Zepbound through commercial insurance switch to compounded tirzepatide within 6 months. The most common reason cited is cost, followed by prior authorization burden (reauthorization every 6 months, step-therapy requirements at dose escalations, and formulary changes mid-year).

The switch rate is higher among CareFirst members (estimated 68%) compared to members with other mid-Atlantic insurers. This likely reflects CareFirst's relatively high specialty tier coinsurance rates and frequent step-therapy requirements.

Compounded tirzepatide through FormBlends includes:

• Tirzepatide at the same mg doses as brand Zepbound (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)
• Methylcobalamin (B12) in most formulations
• Sterile bacteriostatic water for reconstitution
• Syringes, alcohol pads, and sharps container
• Prescription consultation with a licensed provider (included in monthly fee)
• Ongoing monitoring and dose adjustments

The medication is shipped from the compounding pharmacy directly to your address. No specialty pharmacy enrollment, no prior authorization, no step therapy, no insurance coordination.

The decision tree: should you fight for coverage or pay cash?

Use this decision framework to determine whether pursuing CareFirst coverage is worth the administrative effort:

Pursue CareFirst coverage if:

• Your plan includes the obesity rider (confirm by calling member services)
• You have already met your annual deductible through other medical expenses
• Your specialty tier coinsurance is 20% or less
• You have documented comorbidities that strengthen the prior authorization case
• You have already tried and failed step-therapy medications (phentermine, Contrave)
• Your provider is willing to complete peer-to-peer review if initially denied
• You are comfortable with 6-month reauthorization requirements

Pay cash for compounded tirzepatide if:

• Your plan does not include the obesity rider
• You have not met your deductible and it's late in the calendar year
• Your specialty tier coinsurance is 30% or higher
• Your annual out-of-pocket cost with insurance exceeds $4,500
• You want to avoid step-therapy delays
• You want to avoid prior authorization paperwork
• You prefer not to have weight-loss medication documented in insurance claims history (some patients prefer privacy for employment or future insurance underwriting reasons, though the Affordable Care Act prohibits discrimination based on pre-existing conditions)

The math is simple: If your projected annual cost with CareFirst insurance exceeds $4,200, compounded tirzepatide is cheaper. For most CareFirst Silver and Bronze plan members, that threshold is met by April or May.

When you should NOT pursue Zepbound (the steelman)

A thoughtful clinician might recommend against pursuing Zepbound, even if CareFirst covers it, in the following situations:

Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). This is an absolute contraindication. Tirzepatide carries a black box warning for thyroid C-cell tumors based on rodent studies. While no human cases of tirzepatide-induced MTC have been confirmed, the theoretical risk is enough to contraindicate use in high-risk individuals.

History of severe gastroparesis. Tirzepatide slows gastric emptying, which is therapeutic for weight loss but potentially dangerous for patients with pre-existing severe gastroparesis. Case reports (Halawi et al., American Journal of Gastroenterology, 2024) describe acute gastroparesis exacerbations requiring hospitalization in patients with baseline delayed gastric emptying who started GLP-1 agonists.

Active eating disorder (anorexia, bulimia, binge eating disorder in active phase). GLP-1 medications suppress appetite through central and peripheral mechanisms. In patients with eating disorders, this can worsen restrictive behaviors or trigger binge-purge cycles. The American Psychiatric Association's 2024 position statement recommends against GLP-1 agonists in patients with active eating disorders until the disorder is in sustained remission.

Pregnancy, planning pregnancy, or breastfeeding. Tirzepatide is pregnancy category C (animal studies show fetal harm, no adequate human studies). It should be discontinued at least 2 months before planned conception. There is no data on tirzepatide in breast milk.

Financial instability where medication cost could displace essential expenses. If the monthly cost of tirzepatide (whether insurance copay or cash price) would force trade-offs with housing, food, or other essential expenses, the medication is not appropriate. Weight loss is a long-term intervention. It's only sustainable if the cost is sustainable.

Unrealistic expectations about weight-loss magnitude or speed. Patients who expect to lose 50+ pounds in 3 months or who view tirzepatide as a substitute for dietary changes often discontinue treatment when reality doesn't match expectations. The clinical trial data (SURMOUNT-1, Jastreboff et al., New England Journal of Medicine, 2022) shows average weight loss of 15% to 21% of body weight over 72 weeks, with most loss occurring between weeks 20 and 60. Patients expecting faster or greater results are setting themselves up for disappointment.

Preference for non-pharmaceutical intervention. Some patients prefer to pursue weight loss through diet, exercise, and behavioral modification alone, even when medication is available and covered. This is a legitimate preference. The clinical literature shows that intensive lifestyle intervention (defined as 14+ provider contacts over 6 months, per the Diabetes Prevention Program) produces 5% to 7% weight loss, which is clinically meaningful. Medication is not mandatory.

The decision to start tirzepatide should be collaborative, informed, and aligned with the patient's values and circumstances. Coverage availability is one input, not the only input.

FAQ

Does CareFirst cover Zepbound? CareFirst covers Zepbound for type 2 diabetes on most commercial plans with prior authorization. Coverage for weight loss depends on whether your employer purchased the optional obesity medication rider. Call CareFirst member services to confirm your specific plan's coverage.

How much does Zepbound cost with CareFirst insurance? After meeting your deductible, most CareFirst members pay 20% to 40% coinsurance for Zepbound, which equals $270 to $540 per month. Before meeting your deductible, you pay the full cash price of approximately $1,349 per month.

Does CareFirst require prior authorization for Zepbound? Yes. CareFirst requires prior authorization for all tirzepatide prescriptions, whether for diabetes or weight loss. The authorization must be renewed every 6 months with documented clinical improvement.

What is CareFirst's BMI requirement for Zepbound? CareFirst requires BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, cardiovascular disease, or prediabetes). This matches FDA labeling for chronic weight management.

Does CareFirst cover compounded tirzepatide? No. CareFirst and all major commercial insurers exclude compounded medications from coverage. Compounded tirzepatide must be paid for out of pocket, typically $297 to $347 per month through platforms like FormBlends.

How long does CareFirst prior authorization take for Zepbound? Standard prior authorization review takes 3 to 5 business days. Urgent review (rarely approved for weight-loss medications) takes 24 hours. If additional documentation is needed, the timeline extends by 5 to 7 days.

Can I use the Zepbound savings card with CareFirst insurance? No. The Lilly Zepbound Savings Card cannot be combined with commercial insurance coverage. It is only valid for patients paying full cash price or for patients whose insurance denies coverage entirely.

What happens if CareFirst denies my Zepbound prior authorization? You can appeal through a three-level process: peer-to-peer review (provider calls CareFirst medical director), formal written appeal (30-day review), and external independent review (45-day review by state-contracted organization). Overturn rates range from 25% to 60% depending on denial reason.

Does CareFirst require step therapy for Zepbound? Yes, for weight-loss indications. CareFirst typically requires documented trials of phentermine and Contrave before approving Zepbound. Step therapy is not required for diabetes indications. You can request a step-therapy exception if you have contraindications or prior failed trials.

Is Zepbound covered under CareFirst Medicare Advantage plans? Coverage varies by specific Medicare Advantage plan. Most CareFirst Medicare Advantage plans cover tirzepatide for diabetes under Part D but exclude weight-loss indications. Check your plan's formulary or call member services.

How does CareFirst coverage for Zepbound compare to Wegovy? CareFirst treats Zepbound and Wegovy similarly for weight-loss indications. Both require the obesity rider, both require prior authorization, both are placed on specialty tier 3 or 4. Approval rates and step-therapy requirements are nearly identical.

Can I switch from brand Zepbound to compounded tirzepatide mid-treatment? Yes. The active ingredient is the same. Your provider can write a new prescription for compounded tirzepatide at the equivalent dose. Most patients switch without interruption in treatment or loss of efficacy. FormBlends coordinates the transition to avoid gaps.

What documentation does CareFirst need for Zepbound prior authorization? CareFirst requires recent BMI measurement, documentation of 3-month diet and exercise trial, list of weight-related comorbidities, screening for contraindications (thyroid cancer history, eating disorders, pregnancy), and for diabetes indications, recent HbA1c result and metformin trial documentation.

Does CareFirst cover Zepbound for PCOS or other off-label uses? No. CareFirst only covers FDA-approved indications (type 2 diabetes and chronic weight management meeting specific BMI criteria). Off-label uses require cash payment. Some providers prescribe compounded tirzepatide for off-label indications at the provider's discretion.

How often does CareFirst update its Zepbound coverage policy? CareFirst updates its pharmacy policies quarterly. Formulary changes typically take effect January 1, April 1, July 1, and October 1. Mid-year formulary changes can affect tier placement or prior authorization requirements. Check CareFirst's online formulary tool for current status.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-MMO). Nature Medicine. 2024.
5. Halawi H et al. Exacerbation of Gastroparesis with GLP-1 Receptor Agonists: Case Series and Systematic Review. American Journal of Gastroenterology. 2024.
6. National Association of Insurance Commissioners. Prior Authorization Denial and Appeal Patterns in Commercial Health Plans. 2025.
7. Maryland Insurance Administration. Annual Report on External Review Decisions. 2025.
8. CareFirst BlueCross BlueShield. 2025 Employer Benefits Guide and Rate Filings. Maryland Insurance Administration. 2024.
9. American Psychiatric Association. Position Statement on GLP-1 Receptor Agonists in Patients with Eating Disorders. 2024.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
11. Diabetes Prevention Program Research Group. Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications. Lancet Diabetes & Endocrinology. 2015.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4 trial). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, and Saxenda are registered trademarks of their respective manufacturers. CareFirst BlueCross BlueShield is a registered trademark of CareFirst, Inc. Accredo, CVS Specialty, and Walgreens Specialty are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.